Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. Please note that this position can be based in San Diego, CA OR San Francisco, CA OR Princeton, NJ. Acadia's hybrid model requires this role to work in our office three days per week on average. Position Summary The Executive Director will lead the design and implementation of disease and drug mechanism of action (MoA) studies to advance therapeutics into and through clinical development. The position requires deep experience in translational sciences, proven leadership and mentoring skills, hands-on rare disease experience, strong understanding of clinical biomarker development, and a deep understanding of drug development from discovery through late-stage clinical studies. The ability to synthesize complex biological concepts and data into clearly communicated actionable insights is critical, as is a track record of successful partnering with functions across the drug development paradigm.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree